Abstract
Accumulation of misfolded proteins in proteinaceous inclusions is a prominent pathological feature common to many agerelated neurodegenerative diseases, including Parkinsons disease, Alzheimers disease, Huntingtons disease, and amyotrophic lateral sclerosis. In cultured cells, when the production of misfolded proteins exceeds the capacity of the chaperone refolding system and the ubiquitin-proteasome degradation pathway, misfolded proteins are actively transported to a cytoplasmic juxtanuclear structure called an aggresome. Aggresome formation is recognized as a cytoprotective response serving to sequester potentially toxic misfolded proteins and facilitate their clearance by autophagy. Recent evidence indicates that aggresome formation is mediated by dynein/dynactin-mediated microtubule- based transport of misfolded proteins to the centrosome and involves several regulators, including histone deacetylase 6, E3 ubiquitin-protein ligase parkin, deubiquitinating enzyme ataxin-3, and ubiquilin-1. Characterization of the molecular mechanisms underlying aggresome formation and its regulation has begun to provide promising therapeutic targets that may be relevant to neurodegenerative diseases. In this review, we provide an overview of the molecular machinery controlling aggresome formation and discuss potential useful compounds and intervention strategies for preventing or reducing the cytotoxicity of misfolded and aggregated proteins.
Keywords: Neurodegenerative diseases, aggresome, HDAC6, parkin, ataxin-3, ubiquilin-1, inclusion body, protein misfolding
Current Medicinal Chemistry
Title: Aggresome Formation and Neurodegenerative Diseases: Therapeutic Implications
Volume: 15 Issue: 1
Author(s): L. S. Chin, J. A. Olzmann and L. Li
Affiliation:
Keywords: Neurodegenerative diseases, aggresome, HDAC6, parkin, ataxin-3, ubiquilin-1, inclusion body, protein misfolding
Abstract: Accumulation of misfolded proteins in proteinaceous inclusions is a prominent pathological feature common to many agerelated neurodegenerative diseases, including Parkinsons disease, Alzheimers disease, Huntingtons disease, and amyotrophic lateral sclerosis. In cultured cells, when the production of misfolded proteins exceeds the capacity of the chaperone refolding system and the ubiquitin-proteasome degradation pathway, misfolded proteins are actively transported to a cytoplasmic juxtanuclear structure called an aggresome. Aggresome formation is recognized as a cytoprotective response serving to sequester potentially toxic misfolded proteins and facilitate their clearance by autophagy. Recent evidence indicates that aggresome formation is mediated by dynein/dynactin-mediated microtubule- based transport of misfolded proteins to the centrosome and involves several regulators, including histone deacetylase 6, E3 ubiquitin-protein ligase parkin, deubiquitinating enzyme ataxin-3, and ubiquilin-1. Characterization of the molecular mechanisms underlying aggresome formation and its regulation has begun to provide promising therapeutic targets that may be relevant to neurodegenerative diseases. In this review, we provide an overview of the molecular machinery controlling aggresome formation and discuss potential useful compounds and intervention strategies for preventing or reducing the cytotoxicity of misfolded and aggregated proteins.
Export Options
About this article
Cite this article as:
Chin S. L., Olzmann A. J. and Li L., Aggresome Formation and Neurodegenerative Diseases: Therapeutic Implications, Current Medicinal Chemistry 2008; 15 (1) . https://dx.doi.org/10.2174/092986708783330692
DOI https://dx.doi.org/10.2174/092986708783330692 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Ion Channels, Cellular Carriers and Na(+)/K(+)/ATPase by Janus Kinase 3
Current Medicinal Chemistry Synthesis of Functionalized Chromenes from Meldrum’s Acid, 4- Hydroxycoumarin, and Ketones or Aldehydes
Combinatorial Chemistry & High Throughput Screening Adeno-Associated Virus (AAV) Vectors in the CNS
Current Gene Therapy Potential Drugs and Methods for Preventing or Delaying the Progression of Huntington's Disease
Recent Patents on CNS Drug Discovery (Discontinued) Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Current Pharmaceutical Design A Glimpse of Matrix Metalloproteinases in Diabetic Nephropathy
Current Medicinal Chemistry Current Update on Synopsis of miRNA Dysregulation in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Flavonoids in Neurodegeneration: Limitations and Strategies to Cross CNS Barriers
Current Medicinal Chemistry Animal Models in Neurology: Drawbacks and Opportunities
Current Pharmaceutical Design A Genetic Dissection of Antipsychotic Induced Movement Disorders
Current Medicinal Chemistry Possible Therapeutic Targets in Cardiac Myocyte Apoptosis
Current Pharmaceutical Design Therapeutic Opportunities for Trophic Factors in Brain Inflammation
Current Pharmaceutical Analysis A Novel Relationship for Schizophrenia, Bipolar and Major Depressive Disorder Part 6: A Hint from Chromosome 6 High Density Association Screen
Current Molecular Medicine Spinal Cord Injury Changes Cytokine Transport
CNS & Neurological Disorders - Drug Targets Nanoneuromedicines for Neurodegenerative Diseases
Nanoscience & Nanotechnology-Asia Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets Modulation of Neuro-Inflammation and Vascular Response by Oxidative Stress Following Cerebral Ischemia-Reperfusion Injury
Current Medicinal Chemistry Adult Neural Stem Cells: Response to Stroke Injury and Potential for Therapeutic Applications
Current Stem Cell Research & Therapy Promises and Challenges of Adult Stem Cells in Cancer Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Deacetylase Inhibitors Modulate the Myostatin/Follistatin Axis without Improving Cachexia in Tumor-Bearing Mice
Current Cancer Drug Targets